Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer

NCT03098030 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

483

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

BIOLOGICAL: Dinutuximab
DRUG: Irinotecan
DRUG: Topotecan

Sponsor

United Therapeutics